| SynCore Biotechnology has received the approval from OGYEI to conduct Phase III clinical trial for its drug SB05PC (EndoTAG®-1) in Hungry, which is the second country from Europe to join the study. Regarding the high incident and mortality rate of pancreatic cancer in Hungry, we are anticipated to introduce new treatment to meet to market demand.
About SynCore Biotechnology Co., Ltd SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutical company focusing on creating values of new drugs by R&D and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI). SynCore utilizes and in-licenses the unique technologies from all over the world to develop new drugs for unmet medical needs with great marketing potential. Syncore’s comprehensive pipeline portfolio of new drugs in the area of oncology, ophthalmology, dermatology and infectious diseases. Meet us at:
|